Ads
related to: new treatment for lgl leukemia
Search results
Results From The WOW.Com Content Network
Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood. [1] It is divided in two main categories: T-cell LGL leukemia (T-LGLL) and natural-killer (NK)-cell LGL leukemia (NK-LGLL).
Aggressive NK-cell leukemia is a disease with an aggressive, systemic proliferation of natural killer cells (NK cells) and a rapidly declining clinical course. [ 1 ] [ 2 ] [ 3 ] It is also called aggressive NK-cell lymphoma .
Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, with supportive and palliative care provided as needed. [3] [6] Certain types of leukemia may be managed with watchful waiting. [3] The success of treatment depends on the type of leukemia and the age of the person.
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein. [8]
Idelalisib (trade name Zydelig; codenamed CAL-101, GS-1101; PIK3CD inhibitor): FDA-approved in July 2014 for treatment of three types of blood cancers: treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with rituximab, treatment of relapsed small lymphocytic lymphoma after at least two prior systemic therapies, and treatment of follicular lymphoma (FL) after ...
The center's director, Thomas P. Loughran Jr., discovered and is considered a leading expert in large granular lymphocytic (LGL) leukemia. He succeeded Michael J. Weber, who stepped down in 2013 after twelve years of service. [10] UVA Cancer Center is funded as a partner in the federal Cancer Moonshot. [11]